Jasper Therapeutics, Inc. (JSPR)

Market Cap	16.37M
Revenue (ttm)	n/a
Net Income	n/a
EPS	n/a
Shares Out	1.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,364
Open	15.04
Previous Close	14.75
Day's Range	13.64 - 15.45
52-Week Range	9.45 - 72.60
Beta	3.30
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 24, 2026

About JSPR

Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a no...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 22
• Stock Exchange: Nasdaq
• Ticker Symbol: JSPR
• Website: https://jaspertx.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 11, 2026

Data Sources Report a data error